Actually there is growing evidence that such tumors from MMR gene germline mutation carriers are part of LS tumor spectrum and relative risk of GC in LS mutation carriers is reported to be higher by 4–19 compared to the general population in western countries [50,51,69] at least by 2-fold in endemic areas in Asia [16] as our investigated region. This evidence concerns the gene MRC1 and neoplasm.